Stay updated with breaking news from Mark Lappe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Inhibrx announced an agreement with Sanofi on Tuesday, under which Sanofi subsidiary Aventis will acquire all assets and liabilities associated with INBRX-101, a recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently being trialled for alpha-1 antitrypsin deficiency (AATD) treatment.
Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.
:max_bytes(150000):strip_icc()/GettyImages-1238176718-7fbc79c8e2914ff8bff797f9e558f3e8.jpg)
Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases.
Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. for $1.4 billion on January 22, 2024. Immediately prior to the closing of the merger, all non-101 assets and liabilities,...